Refer-A-Friend Program

Sneeze, Wheeze and Itch Associates, LLC
Sneeze, Wheeze & Itch Associates, LLC

Clinical Trial: Call for Moderate-Severe Eczema/Atopic Dermatitis Patients

Are you 18 years old and above?

Have you had moderate to Severe Eczema/Atopic Dermatitis for at least three years?

We accept participants of all sexes.

You may be eligible for a study and receive compensation for time and travel.

See if you are eligible by filling out this form. You will be contacted by our staff as soon as possible.

BRIEF SUMMARY
This study aims to see if ADX-914 are safe and effective to treat people with eczema. We’ll compare the results of the medication against a placebo treatment.

CONDITIONS
Atopic Dermatitis

INTERVENTION / TREATMENT
Medication, Placebo

ENROLLMENT NATIONWIDE (ESTIMATED)
110

STUDY TYPE
Interventional

PHASE
Phase 2

AGES ELIGIBLE FOR STUDY
12 Years and above (Adult, Older Adult)

SEXES ELIGIBLE FOR STUDY
All

ACCEPTS HEALTHY VOLUNTEERS
No

Read on Clinicaltrial.gov: https://clinicaltrials.gov/study/NCT05509023

Why participate in clinical research? All of the medicines you currently take for your health were first studied in clinical trials before the FDA approved them.  It is a great way to help your community, while getting close care and monitoring by doctors you know.

See other active clinical trials here.

Page updated: August 2023

________________________________

Study Participation Details

About Trials and SWIA CRC

All our clinical research opportunities are FDA regulated and are sponsored by pharmaceutical companies or government agencies to develop new treatments or to study additional diseases for treatments currently approved for prescription. Each trial is conducted at many academic and private research centers that have been carefully chosen for their experience and reputation.  SWIA Clinical Research Center, is a separate company affiliated with Midwest Allergy Sinus & Respiratory has operated over 1000 trials over the past 30 years and has been involved in developing many of the allergy and respiratory medicines you may be familiar with, including Zyrtec, Allegra, Singulair, Advair, Symbicort, Breztri, Trelegy, Nasonex, Xhance, Grastek, Ragwitek, Xolair, Dupixent, Palforzia, Stelara, Opzelura, Cibinqo, and Rinvoq, to name a few. Our highly trained clinical research staff follow strict protocols, which are in place to ensure safety, uniformity, and integrity.  We have conducted studies with Volunteers from all walks of life, from infancy through advanced ages.

Contact us for more information, SWIA Clinical Research Dept.: Stephanie 309-451-7509 or Kady 309-452-0995 Ext 7522.  You can also email us at research@asthma2.com, or fill out this contact this form.

Clinical Study: Peanut Allergy (ALK)

Adults and children ages 4 to 65 may be eligible to participate in a clinical study for peanut allergies.

Study participants will receive study-related care at no cost.

See if you are eligible for this paid study by filling out this form.
You will be contacted by our staff as soon as possible.

FARE in collaboration with ALK Pharmaceuticals, are working on a study to assess the safety and tolerability of a once-daily sublingual immunotherapy (SLIT) tablet for peanut allergy. The peanut SLIT-tablet is being developed for peanut-allergic patients to reduce allergic reactions that may occur following accidental exposure to peanut. By desensitizing patients to peanut protein, tolerance is increased and consequently protects against allergic reactions upon accidental peanut exposure.

Read on Clinicaltrial.gov: https://clinicaltrials.gov/study/NCT05440643

Why participate in clinical research? All of the medicines you currently take for your health were first studied in clinical trials before the FDA approved them.  It is a great way to help your community, while getting close care and monitoring by doctors you know.

See other active clinical trials in Normal, IL or Springfield, IL here.

Page updated: January 2024

Clinical Study: Eosinophilic Esophagitis / EoE (CROSSING 2023-2027)

Are you an adult between 12-80 or with a child 12 years old or above?

Do you have physician-documented Eosinophilic Esophagitis (EoE)?

Read: What is EoE? and Top 11 FAQs about EoE

Do you have difficulty swallowing food?

We accept participants of all sexes.

You may be eligible for a study with compensation for time and travel to our site in Normal, IL.

See if you are eligible by filling out this form. You will be contacted by our staff as soon as possible.

BRIEF SUMMARY
Researchers are testing if a new medicine named tezepelumab, given as a shot with a special syringe, works better and is safe for people with eosinophilic esophagitis, compared to a placebo.

CONDITIONS
EoE (Eosinophilic Esophagitis)

ENROLLMENT GLOBALLY (ESTIMATED)
360

STUDY TYPE
Interventional

PHASE
Phase 3

AGES ELIGIBLE FOR STUDY
12-80 Years (Child,  Adult,  Older Adult)

SEXES ELIGIBLE FOR STUDY
All

ACCEPTS HEALTHY VOLUNTEERS
No

Read on Clinicaltrial.gov: https://clinicaltrials.gov/study/NCT05583227

Why participate in clinical research? All of the medicines you currently take for your health were first studied in clinical trials before the FDA approved them.  It is a great way to help your community, while getting close care and monitoring by doctors you know.

See other active clinical trials here.

Page updated: December 2023

Clinical Study: Severe Asthma NIMBLE (Continued Care) 2023 2024

Are you an adult or with a child 12 years old or above who has severe asthma?

Do you have documented physician diagnosis of asthma for 2 years or more?

We accept participants of all sexes.

You may be eligible for a study with compensation for time and travel up to $2000.

See if you are eligible by filling out this form. You will be contacted by our staff as soon as possible.

Image Credit: Polina Tankilevitch (Pexel)

BRIEF SUMMARY
Throughout the study, all participants will continue their non-biologic Baseline standard of care (SoC) asthma treatment. The study will assess switching types of biologic medication.

CONDITIONS
Asthma

INTERVENTION / TREATMENT
Biological

ENROLLMENT GLOBALLY (ESTIMATED)
1700

STUDY TYPE
Interventional

PHASE
Phase 3

AGES ELIGIBLE FOR STUDY
12 Years and older (Child,  Adult,  Older Adult)

SEXES ELIGIBLE FOR STUDY
All

ACCEPTS HEALTHY VOLUNTEERS
No

Read on Clinicaltrial.gov: https://clinicaltrials.gov/study/NCT04718389

Why participate in clinical research? All of the medicines you currently take for your health were first studied in clinical trials before the FDA approved them.  It is a great way to help your community, while getting close care and monitoring by doctors you know.

See other active clinical trials here.

Page updated: December 2023

Clinical Trial: Call for Moderate-Severe Eczema Patients (SIGNAL-AD)

Are you 18 years old and above?

Have you had moderate to Severe Eczema/Atopic Dermatitis for at least three years?

We accept participants of all sexes.

You may be eligible for a study and receive compensation for time and travel.

See if you are eligible by filling out this form. You will be contacted by our staff as soon as possible.

BRIEF SUMMARY
This study aims to see if ADX-914 are safe and effective to treat people with eczema. We’ll compare the results of the medication against a placebo treatment.

CONDITIONS
Atopic Dermatitis

INTERVENTION / TREATMENT
Medication, Placebo

ENROLLMENT NATIONWIDE (ESTIMATED)
110

STUDY TYPE
Interventional

PHASE
Phase 2

AGES ELIGIBLE FOR STUDY
12 Years and above (Adult, Older Adult)

SEXES ELIGIBLE FOR STUDY
All

ACCEPTS HEALTHY VOLUNTEERS
No

Read on Clinicaltrial.gov: https://clinicaltrials.gov/study/NCT05509023

Why participate in clinical research? All of the medicines you currently take for your health were first studied in clinical trials before the FDA approved them.  It is a great way to help your community, while getting close care and monitoring by doctors you know.

See other active clinical trials here.

Page updated: August 2023

________________________________

Study Participation Details

About Trials and SWIA CRC

All our clinical research opportunities are FDA regulated and are sponsored by pharmaceutical companies or government agencies to develop new treatments or to study additional diseases for treatments currently approved for prescription. Each trial is conducted at many academic and private research centers that have been carefully chosen for their experience and reputation.  SWIA Clinical Research Center, is a separate company affiliated with Midwest Allergy Sinus & Respiratory has operated over 1000 trials over the past 30 years and has been involved in developing many of the allergy and respiratory medicines you may be familiar with, including Zyrtec, Allegra, Singulair, Advair, Symbicort, Breztri, Trelegy, Nasonex, Xhance, Grastek, Ragwitek, Xolair, Dupixent, Palforzia, Stelara, Opzelura, Cibinqo, and Rinvoq, to name a few. Our highly trained clinical research staff follow strict protocols, which are in place to ensure safety, uniformity, and integrity.  We have conducted studies with Volunteers from all walks of life, from infancy through advanced ages.

Contact us for more information, SWIA Clinical Research Dept.: Stephanie 309-451-7509 or Kady 309-452-0995 Ext 7522.  You can also email us at research@asthma2.com, or fill out this contact this form.

Great News: Positive Top-Line Result for Safety and Efficacy of a Non-Steroidal Topical Treatment for Atopic Dermatitis in Children (MASA SWIA)

On July 11, 2023, MASA’s research team at Sneeze Wheeze and Itch Associates received great news regarding the positive top-line research results on the safety and efficacy of a non-steroidal topical treatment for Atopic Dermatitis (AD) in children. The SWIA research team, led by Dr. Siri as Principal Investigator, contributed to the pivotal Phase 3 study for ruxolitinib cream, along with 98 other research centers worldwide!

Incyte, a pharmaceutical company, has released positive results from a study evaluating a cream called ruxolitinib (Opzelura®) for the treatment of atopic dermatitis (AD) in children. AD is a chronic skin condition that affects about 13% of children in the U.S. The study showed that more patients treated with ruxolitinib cream achieved successful treatment compared to those treated with a non-medicated cream. The cream was well-tolerated, and no new safety concerns were observed. Incyte plans to discuss these positive results with regulatory agencies to determine the next steps.

Atopic dermatitis (AD), the most common type of eczema, affects millions of people in the U.S., particularly children. It is characterized by inflamed and itchy skin, which can cause discomfort and infections. The recently completed study, called TRuE-AD3, enrolled over 300 children aged 2 to 12 years who had been diagnosed with AD for at least three months. The primary goal of the study was to assess the proportion of patients achieving successful treatment based on specific criteria. The study results will be presented at a scientific meeting.

Opzelura cream is a formulation of ruxolitinib, a medication that targets specific pathways in the body associated with inflammation. It has already been approved for the treatment of vitiligo and atopic dermatitis in the U.S. Opzelura offers a potential non-steroidal topical therapy for children with AD, which could provide relief from symptoms and improve their quality of life. Incyte holds the worldwide rights for the development and commercialization of ruxolitinib cream.

Read about the clinical trial here: https://classic.clinicaltrials.gov/ct2/show/NCT04921969
Read more about the announcement here: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-positive-topline-results-phase-3-trial
Follow Sneeze, Wheeze and Itch Associates on Facebook: https://www.facebook.com/SWIA.Clinical.Research

Refer-A-Friend Program

REFER A QUALIFYING FRIEND,

AND YOU COULD RECEIVE UP TO $25!

 

How It Works

To refer a friend or family member for a clinical trial at SWIA and earn up to $25, simply:

1. Print and fill out a Refer-A-Friend coupon (click here to download).

2. Your friend or family member must contact SWIA about the research study and present this coupon at their first study visit.

3. If your friend or family member qualifies to screen for the study and enrolls (randomizes and receives study medication, study treatment or placebo), the referrer (YOU) will earn $25!

Please Remember

-You can refer as many people as you want and there is no limit to how much money you can make!

-To be eligible, the friend or family member that you refer must be new to our database, and YOU must be in our database as well.  To be added to our database, call 309-452-0995 and ask to speak to a research coordinator.

-The decision to participate in a study is up to your friend or family member.

-Refer-A-Friend payments are made AFTER your friend or family member has completed the randomization visit.

-For questions about the Refer-A-Friend program or to inquire about the status of a referral, please call 309-452-0995.

Sneeze, Wheeze and Itch Associates, LLC

For more information regarding current studies, please call 309-452-0995 and ask to speak to a coordinator.